Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ceptaris raises $10mm through Series D-1 round

Executive Summary

Ceptaris Therapeutics Inc. (spec pharma focused on cancer) raised $10mm through its Series D-1 round. New investor Third Point was joined by returning backers Vivo Ventures, Palo Alto Investors, Burrill & Co., Aperture Venture Partners, Osage, BioAdvance, and 26 other undisclosed investors. Some of the proceeds will be used to address a Complete Response Letter recently received by the FDA regarding the NDA for Ceptaris' mechlorethamine gel, which is in development for the early stages of a type of cutaneous T-cell lymphoma called mycosis fungoides.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies